10.02.19
Stacey Treichler, group product manager for Catalent Biologics, highlights some of the company's major accomplishments over the past year.
Related Breaking News
-
Biologics, Proteins, Vaccines | Breaking News | cGMP Manufacture | Industry News
Lonza Further Invests in Drug Product Manufacturing Capabilities
New filling line to process various modalities, including monoclonal antibodies, bioconjugates, viral vectors, and other gene therapy products.09.22.21
-
Breaking News | Clinical Trials
pHOXBIO Unveils Trial Results from COVID Prophylactic Nasal Spray
According to the study, the novel prophylactic nasal spray prevented infection from SARS-CoV-2, the virus that causes COVID-19.09.22.21
-
Breaking News | Drug Development | Drug Discovery | Industry News
Rentschler Biopharma to Support Albert Einstein Discovery Center
Donates 50,000 Euros to support the creation of the discovery and activity center in Ulm.09.22.21
-
Breaking News | Industry News | Laboratory Testing
Metrion Biosciences Expands into New Cambridge HQ
New 12,000 sq. ft. Cambridge, UK premises more than doubles lab space.09.22.21
-
Biologics, Proteins, Vaccines | Breaking News | Clinical Trials
Immunic Inc. Signs In-License Agreement with University Medical Center Goettingen, Germany
Covers the combination of DHODH inhibitors and nucleoside analogues to treat viral infections, including Covid-19.09.22.21
-
Breaking News | Drug Development | Industry News
Veklury Reduced Risk of Hospitalization in High-Risk COVID-19 Patients
Veklury demonstrated a statistically significant 87% reduction in risk for the composite primary endpoint of COVID-19 related hospitalization.09.22.21
-
Breaking News | Clinical Trials
First Patient is Dosed with Triumvira's Investigational TAC-T Cell Adoptive Immunotherapy
TAC01-HER2 was developed for the treatment of HER2-overexpressing cancers.09.21.21
-
Biologics, Proteins, Vaccines | Breaking News | Industry News
J&J Data Confirms Strong and Long-Lasting Protection of COVID-19 Vax
Phase 3 ENSEMBLE trial shows booster shot at two months provided 94 percent protection against COVID-19 in the U.S.09.21.21
-
Breaking News | Formulation Development
Recro Pharma Signs Renewable Energy Agreement with Georgia Power
Will purchase 1.2 million renewable energy credits through Georgia Power’s Simple Solar Program.09.21.21
-
Biologics, Proteins, Vaccines | Breaking News | cGMP Manufacture | Clinical Trial Materials | Industry News
Naobios to Manufacture FluGen’s M2SR Flu Vax Candidate
Will initiate the GMP manufacturing of the clinical batches of FluGen’s M2SR influenza vaccine candidate for upcoming clinical trials.09.21.21
-
Biologics, Proteins, Vaccines | Breaking News | Drug Development | Industry News
CuriRx Launches CuriLytics Platform for Biotherapeutic Development
To provide CMC analytical services to support complex biotherapeutic development using high resolution mass spectrometry.09.21.21
-
Biologics, Proteins, Vaccines | Reader Showcase
Thermo Fisher Launches Gibco AAV Production System
Aims to address the need to make adeno-associated virus (AAV) production more efficient and scalable.09.20.21
-
Breaking News | Collaborations & Alliances | Drug Development | Industry News
Oxford Bio Advances Boehringer Oncology Candidate
Receives another milestone payment from Boehringer Ingelheim for progressing a second oncology drug candidate (BI 765049) into the clinic.09.20.21
-
Breaking News | Promotions & Moves
Rentschler Biopharma Appoints Dr. Christian Schetter as Chief Scientific Officer
Schetter has a proven track record across the entire biopharmaceutical value chain.09.20.21
-
Breaking News | cGMP Manufacture | Drug Development | Industry News
Everest Medicines, Sinovent, SinoMab Enter Global BTK Inhibitor Mfg. Pact
To develop, produce and commercialize XNW1011, a covalent reversible BTK inhibitor, globally for the treatment of renal diseases.09.17.21
